Second generation anti-cyclic citrullinated peptide (anti-CCP2) antibodies can replace other anti-filaggrin antibodies and improve rheumatoid arthritis diagnosis

Scand J Rheumatol. 2004;33(4):218-20. doi: 10.1080/03009740410005403.

Abstract

We compared the diagnostic performance of anti-cyclic citrullinated peptide antibodies detected with second-generation enzyme immunoassay (anti-CCP2) with that of IgM-rheumatoid factor (RF), anti-perinuclear factor (APF), and anti-keratin antibodies (AKA). The sensitivity of anti-CCP2 was better than that of APF and AKA: they were detected in 25% rheumatoid arthritis (RA) patients without detectable APF or AKA. Their specificity, evaluated in other inflammatory rheumatic disease, was similar to that of APF and AKA. Despite the lower specificity, IgM-RF in combination with anti-CCP2 is interesting, as they do not completely overlap. Anti-CCP2 antibody detection seems to be a good alternative to other anti-filaggrin antibodies in the diagnosis of RA.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Arthritis, Rheumatoid / diagnosis*
  • Arthritis, Rheumatoid / immunology
  • Autoantibodies / analysis*
  • Autoantibodies / immunology
  • Diagnosis, Differential
  • Filaggrin Proteins
  • Humans
  • Immunoenzyme Techniques
  • Immunoglobulin M / analysis
  • Intermediate Filament Proteins / analysis
  • Intermediate Filament Proteins / immunology
  • Peptides, Cyclic / immunology*
  • Rheumatic Diseases / diagnosis
  • Rheumatoid Factor / analysis
  • Rheumatoid Factor / immunology
  • Sensitivity and Specificity

Substances

  • Autoantibodies
  • FLG protein, human
  • Filaggrin Proteins
  • Immunoglobulin M
  • Intermediate Filament Proteins
  • Peptides, Cyclic
  • cyclic citrullinated peptide
  • Rheumatoid Factor